Loading cancer entity…
Loading cancer entity…
Clinical trials
74 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | active not recruiting | Phase 2 | 36 | Robert R. McWilliams, MDOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04551352 |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas |
| completed |
| Phase 1 |
| 20 |
| Hoffmann-La RocheINDUSTRY |
| 6 |
| Oct 3, 2022 |
| clinicaltrials |
| NCT04353050 | Atypical MOLes and Melanoma Early Detection Study (MoleMed)(MoleMed) | unknown | N/A | 350 | Russian Academy of Medical SciencesOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04180995 | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04462965 | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | unknown | Phase 2 | 294 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04622566 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 26 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04472806 | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma(MTAM) | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT03941795 | Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma(BJCH-MM-0624) | unknown | Phase 2 | 99 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT03602547 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | unknown | Phase 2 | 40 | AnewPharmaINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 14, 2019 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT03138642 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01395121 | A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread(NICAM) | completed | Phase 2 | 29 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 8, 2017 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00110019 | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 3 | 823 | National Cancer Institute (NCI)NIH | 2 | Oct 19, 2015 | clinicaltrials |
| NCT00085189 | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2023source: clinicaltrials